Graduate School of MedicineKorea University, Seoul 136-705, Republic of Korea.
Graduate School of MedicineKorea University, Seoul 136-705, Republic of Korea
J Mol Endocrinol. 2014 Jun;52(3):T15-27. doi: 10.1530/JME-13-0137. Epub 2014 Mar 5.
Glucagon-like peptide 1 (GLP1) is an intestinal incretin that regulates glucose homeostasis through stimulation of insulin secretion from pancreatic β-cells and inhibits appetite by acting on the brain. Thus, it is a promising therapeutic agent for the treatment of type 2 diabetes mellitus and obesity. Studies using synteny and reconstructed ancestral chromosomes suggest that families for GLP1 and its receptor (GLP1R) have emerged through two rounds (2R) of whole genome duplication and local gene duplications before and after 2R. Exon duplications have also contributed to the expansion of the peptide family members. Specific changes in the amino acid sequence following exon/gene/genome duplications have established distinct yet related peptide and receptor families. These specific changes also confer selective interactions between GLP1 and GLP1R. In this review, we present a possible macro (genome level)- and micro (gene/exon level)-evolution mechanisms of GLP1 and GLP1R, which allows them to acquire selective interactions between this ligand-receptor pair. This information may provide critical insight for the development of potent therapeutic agents targeting GLP1R.
胰高血糖素样肽 1(GLP1)是一种肠道肠促胰岛素,通过刺激胰腺β细胞分泌胰岛素和作用于大脑来调节葡萄糖稳态。因此,它是治疗 2 型糖尿病和肥胖症的有前途的治疗剂。使用同线性和重建的祖先染色体的研究表明,GLP1 及其受体(GLP1R)的家族通过两轮(2R)全基因组复制和 2R 前后的局部基因复制而出现。外显子重复也促进了肽家族成员的扩张。外显子/基因/基因组重复后氨基酸序列的特定变化建立了独特但相关的肽和受体家族。这些特定的变化还赋予了 GLP1 和 GLP1R 之间选择性相互作用。在这篇综述中,我们提出了 GLP1 和 GLP1R 的可能的宏观(基因组水平)和微观(基因/外显子水平)进化机制,这使得它们能够获得配体-受体对之间的选择性相互作用。这些信息可能为开发针对 GLP1R 的有效治疗剂提供关键的见解。